Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo (original) (raw)

• Frei 3rd E, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998;4:2027–37.
  CAS PubMed Google Scholar
• Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica. 2003;88:201–11.
  CAS PubMed Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.
  Article CAS PubMed Google Scholar
• Laquente B, Viñals F, Germà JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol. 2007;9:93–8.
  Article CAS PubMed Google Scholar
• Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–86.
  CAS PubMed Google Scholar
• Kamat AA, Kim TJ, Landen Jr CN, Lu C, Han LY, Lin YG et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007;67:281–8.
  Article CAS PubMed Google Scholar
• Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–9.
  CAS PubMed Google Scholar
• Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004;64:821–4.
  Article CAS PubMed Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–26.
  Article CAS PubMed Google Scholar
• Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res. 2004;24:397–404.
  CAS PubMed Google Scholar
• Sharma A, Sharma US, Straubinger RM. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 1996;107:265–72.
  Article CAS PubMed Google Scholar
• Huwyler J, Drewe J, Krähenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine. 2008;3:21–9.
  Article CAS PubMed Google Scholar
• Moghimi SM, Patel HM. Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. Biochim Biophys Acta. 1992;1135:269–74.
  Article CAS PubMed Google Scholar
• Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;11(380):561–2.
  Article Google Scholar
• Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752–6.
  CAS PubMed Google Scholar
• Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338:317–26.
  Article CAS PubMed Google Scholar
• Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK et al. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res. 2007;24:2402–11.
  Article CAS PubMed Google Scholar
• Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release. 2000;63:19–30.
  Article CAS PubMed Google Scholar
• Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99–105.
  CAS PubMed Google Scholar
• Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremophor-EL free formulation of paclitaxel. Nanomedicine (Lond). 2007;2:415–23.
  Article CAS Google Scholar
• Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–24.
  Article CAS PubMed Google Scholar
• Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus Cremophor EL-based paclitaxel. Clin Cancer Res. 2006;12:4331–8.
  Article CAS PubMed Google Scholar
• Ashton AW, Yokota R, John G, Zhao S, Suadicani SO, Spray DC et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem. 1999;274:35562–70.
  Article CAS PubMed Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–6.
  Article CAS PubMed Google Scholar
• Bijman MN, Van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006;5:2348–57.
  Article CAS PubMed Google Scholar
• Liu XR, Wu KC, Huang Y, Sun JB, Ke XY, Wang JC et al. In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. Biol Pharm Bull. 2008;31:1215–20.
  Article CAS PubMed Google Scholar
• Aapro MS, Von Minckwitzb G. Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer. EJC Supplements. 2008;6:3–11.
  CAS Google Scholar
• Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model. J Invest Dermatol. 2003;120:476–82.
  Article CAS PubMed Google Scholar
• Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res. 2003;9:2335–41.
  CAS PubMed Google Scholar
• Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 2004;110:117–24.
  Article CAS PubMed Google Scholar
• Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer. 2008;122:452–60.
  Article CAS PubMed Google Scholar
• Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res. 2008;14:4603–11.
  Article CAS PubMed Google Scholar
• Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M et al. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep. 2009;22:321–6.
  CAS PubMed Google Scholar
• Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454–7.
  CAS PubMed Google Scholar
• Ellis AG, Webster LK. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol. 1999;43:13–8.
  Article CAS PubMed Google Scholar
• Marcel Musteata F, Pawliszyn J. Determination of free concentration of paclitaxel in liposome formulation. J Pharm Pharm Sci. 2006;9:231–7.
  PubMed Google Scholar
• Fielding RM. Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet. 1991;21:155–64.
  Article CAS PubMed Google Scholar
• Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci. 2009;98:411–29.
  Article CAS PubMed Google Scholar
• Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57–64.
  CAS PubMed Google Scholar
• Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54:3352–6.
  CAS PubMed Google Scholar